The FDA has given fast-track designation to Diakonos Oncology for its pancreatic cancer vaccine.
The designation allows Diakonos to expedite development and review of the organization's dendritic cell vaccine technology for pancreatic cancer, according to a July 15 news release from the company. Diakonos has also applied the DCV technology to a vaccine for treating glioblastoma.
Daniel Von Hoff, MD, has been named to the Diakonos' scientific advisory board and will advise the clinical development process of the pancreatic cancer vaccine.